New Economy Portfolio Update..took a position in a stock that is expecting an approval in late Aug/Early Sept for their Cologuard..First of its Kind Stool-based DNA Screening Test for Colorectal Cancer.
They are expecting to hear from the FDA Aug 22nd-Sept 7th timeframe.
Alert: bought position in $EXAS at $15.68 working toward full position. There is a 35% short position in the stock.
I’m pleased to report that our FDA facility inspection was completed on July 11th. The inspection was successful. The inspectors spent a week on site and found no deficiencies and no observations. Preparing for and working through this important step in the update process was another example of the outstanding team we have here at Exact. I want to congratulate everyone involved.
We also are working with the agency on the final decision of the post-approval study. We expect final approval within 30 to 45 days. I want to thank the FDA staff for their work on our application.
News 
Market Data 
Discover 
